Upregulation of Tumor Suppressor Protein Neurofibromin in Normal Human Wound Healing and In Vitro Evidence for Platelet Derived Growth Factor (PDGF) and Transforming Growth Factor-β1 (TGF-β1) Elicited Increase in Neurofibromin mRNA Steady-State Levels in Dermal Fibroblasts  by Ylä-Outinen, Heli et al.
Upregulation of Tumor Suppressor Protein Neurofibromin in
Normal Human Wound Healing and In Vitro Evidence for
Platelet Derived Growth Factor (PDGF) and Transforming
Growth Factor-b1 (TGF-b1) Elicited Increase in Neurofibromin
mRNA Steady-State Levels in Dermal Fibroblasts
Heli Yla¨-Outinen,*‡ Vesa Aaltonen,*† Ann-Sofi Bjo¨rkstrand,*† Outi Hirvonen,* Jouni Lakkakorpi,‡
Marko Va¨ha¨-Kreula,*† Matti Laato,† and Juha Peltonen*‡§
Departments of *Medical Biochemistry and †Surgery, University of Turku, Turku, Finland; and Departments of ‡Anatomy and §Dermatology, University of
Oulu, Oulu, Finland
We first studied expression of neurofibromin by immuno-
histochemistry in scars obtained from operations invol-
ving areas of healing wounds. The results demonstrated
increased immunoreactivity for neurofibromin in the
fibroblastic cell population of the lesions when compared
with fibroblasts of apparently healthy perilesional skin,
or those of intact control skin. Furthermore, dermal
fibroblasts of 19 and 34 wk-old fetuses displayed a clearly
detectable immunosignal for neurofibromin. In vitro stud-
ies were designed to investigate the potential effects of
selected growth factors – known to be operative in wound
healing – on neurofibromin mRNA steady-state levels in
cultured fibroblasts. Northern transfer analyses revealed
that different isoforms of platelet derived growth factor
(PDGF) exerted selective effects on the neurofibromin
mRNA levels: PDGF isoform AB elevated neurofibromin
mRNA levels in a concentration-dependent manner when
Neurofibromin is an ubiquitously expressed tumorsuppressor protein encoded by type 1 neurofibrom-atosis (NF1) gene, the mutations of which have beenlinked with type 1 neurofibromatosis (Xu et al, 1990;Marchuk et al, 1991; Basu et al, 1992; DeClue et al,
1992; Legius et al, 1993; von Deimling et al, 1995). One of the
hallmarks of neurofibromatosis are cutaneous neurofibromas, which
represent proliferation of the connective tissue cells of peripheral nerves
and deposition of collagenous extracellular matrix (Lassmann et al,
1975; Peltonen et al, 1984, 1986, 1988; Fleischmajer et al, 1985; Uitto
et al, 1986). Interestingly, somatic mutations of the NF1 gene have
also been found in malignant tissues of otherwise healthy persons, and
the amount of neurofibromin has been reported to be altered in certain
dermal diseases apart from neurofibromatosis (Li et al, 1992; Andersen
et al, 1993b; Johnson et al, 1993; The et al, 1993; Hermonen et al,
1995). Neurofibromin contains a domain that is related to the GTPase
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concentrations of 0.1, 1, 10, and 30 ng per ml were used.
The maximal upregulatory effect of PDGF BB was
reached at a concentration of 1 ng per ml. In contrast,
PDGF AA did not alter the steady-state levels of neurofi-
bromin mRNA. As estimated by RNase protection assay,
transforming growth factor-b1 (TGF-b1) upregulated
neurofibromin gene expression when concentrations of
0.5 and 5 ng per ml were used. Reverse transcription
followed by polymerase chain reaction did not detect
apparent alterations in the ratio of type I/type II neurofi-
bromin isoforms in PDGF- or TGF-b1-treated cultures.
Taken together, our results suggest that expression of
tumor suppressor protein neurofibromin is upregulated
in response to skin injury, and that this upregulation can
be mediated through PDGF and TGF-b. Key words:
neurofibromatosis/pathogenesis/scar/tissue repair. J Invest
Dermatol 110:232–237, 1998
activating protein and accelerates the inactivation of proto-oncogene
ras in various cell types (Xu et al, 1990; Bollag and McCormick, 1992;
Morcos et al, 1996), and apparently interacts with microtubules (Golubic
et al, 1992; Bollag et al, 1993; Gregory et al, 1993). Thus, neurofibromin
is likely to function as a regulator of cell growth and differentiation.
This notion is also supported by findings that mice homozygous for a
mutation in the NF1 gene fail to develop normal structure of, for
example, heart and various neural crest derived tissues, and die in utero
(Brannan et al, 1994; Jacks et al, 1994). The corresponding heterozygous
animals are highly predisposed to the formation of various tumor types
(Jacks et al, 1994). Alternative splicing results in the formation of
different isoforms of neurofibromin mRNA (types I–IV) (Marchuk
et al, 1991; Andersen et al, 1993a; Gutmann et al, 1995). Within adult
human skin, the most intense immunoreaction for neurofibromin is
located in the epidermis, whereas dermal fibroblasts are less intensely
labeled (Hermonen et al, 1995; Peltonen et al, 1995).
The finding that interfering with endogenous ras function can inhibit
the wounding response (Sosnowski et al, 1993), and the suggestion
that mechanical trauma may play a role in the pathogenesis of
neurofibromas (Riccardi, 1981, 1990), led us to test the hypothesis
that neurofibromin has a role in wound repair. For this purpose, we
investigated the expression of neurofibromin in healing surgical wounds
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of otherwise healthy persons. The samples were obtained from patients
undergoing a second operation involving wounds of different ages.
The results were compared with those obtained from normal adult
and fetal skin. Furthermore, fibroblasts cultured from normal adult skin
were exposed to varying concentrations of PDGF and TGF-β1, growth
factors known to have a major role in wound healing (Meyer-Ingold
and Eichner, 1995; Heldin and Westermark, 1996; Roberts and Sporn,
1996), in order to study their potential effects on the expression of the
NF1 gene.
MATERIALS AND METHODS
Tissue samples Post-operative scar samples were collected from 1994 to
1996 at the Department of Surgery, University Hospital of Turku, Finland.
Scar tissues from a total of 26 patients (aged 9–84 y) were used in this study.
The samples were obtained 12 d to 23 mo after the primary operation. Skin
samples used as controls were obtained from operations carried out for cosmetic
reasons from a total of 18 control persons (aged 24–67 y). Skin samples from
two normal human fetuses aged 19 and 34 gestational weeks were obtained
from the Department of Pathology, University of Turku, Finland, with the
appropriate approval of the Joint Ethical Committee of the University Hospital
of Turku and the University of Turku, Finland. No abnormalities were found
in these fetuses either by macroscopic or by microscopic examination at autopsy.
Cell cultures Fibroblast cultures were initiated from skin samples obtained
from a total of 14 control persons. The cells were allowed to migrate from
tissue pieces (1 3 1 3 1 mm) and to proliferate for 2 wk. The cultures were
maintained in Dulbecco’s modification of Eagle’s medium supplemented with
antibiotics (penicillin G, 100 U per ml, and streptomycin sulfate, 50 µg per ml)
and 10% fetal calf serum. To test the effects of PDGF and TGF-β confluent
cultures were incubated in medium supplemented with different growth factors
and with 2% fetal calf serum for a total of 48 h. The medium was changed
once at time point 24 h. Recombinant forms of PDGF AA, PDGF AB, and
PDGF BB and TGF-β1 were purchased from Sigma (St. Louis, MO).
Concentrations of growth factors were as follows: for different isoforms of
PDGF, 0.1, 1, 10, and 30 ng per ml; and for TGF-β1, 0.5 and 5 ng per ml.
Isolation of RNA from cultured fibroblasts was performed as described by
Chomczynski and Sacchi (1987) or Chirgwin et al (1979).
Northern hybridization Samples of total RNA (7.5 µg per lane) were
electrophoresed on 0.9% agarose gels under denaturing conditions, transferred
to nylon membranes (Zeta-probe, Bio-Rad Laboratories, Hercules, CA) and
immobilized by heating at 80°C for 2 h. The RNA filters were prehybridized
overnight in a solution containing 50% formamide, 0.25 M Na2PO4.H2O,
pH 7.2, 0.25 M NaCl, 7% sodium dodecyl sulfate (SDS), and 1 mM ethylenedia-
minetetraacetic acid disodium salt-2-hydrate. Hybridization was performed for
20 h in the same solution containing a radiolabeled human neurofibromin
sequence specific 1.2 kb cDNA probe that was produced by polymerase chain
reaction (PCR) as described earlier (Nishi et al, 1991), subcloned into pBluescript
vector, and sequenced. The probes were labeled radioactively with [α32P]dCTP
using a random primed DNA labeling kit (Boehringer, Mannheim, Germany).
After hybridization, the filters were washed twice in 2 3 standard saline citrate/
0.1% SDS at 20°C for 5 min and twice in 0.1 3 standard saline citrate/0.1%
SDS at 55°C for 10 min. After washing, the filters were exposed to X-ray films
(X-Omat, Eastman Kodak, Rochester, NY) at –70°C for 4–28 d. The intensities
of hybridization signals were quantitated using a laser scanning densitometer
(LKB, Bromma, Sweden). For illustrations, the X-ray films were scanned to
digital format with an original resolution of 200 dpi (Arcus Agfa Professional
image scanner, Agfa-Gevaert, Mortsel, Belgium), and exposed to black and white
photographic film using Agfa Procolor Premier apparatus (Wilmington, MA).
RNase protection assay For detection of neurofibromin mRNA by RNase
protection assay, a neurofibromin sequence specific cDNA was amplified
by RT-PCR and subcloned to pBluescript vector. Specifically, primers 59
CAGAATTCCCCCCTCAACTTCGAAGT 39 and 59 GCGTGCTGCATC-
AAAGTTGCTTTTCAC 39 (Nishi et al, 1991) were used to amplify a 303 bp/
366 bp region corresponding to neurofibromin. The 303 bp PCR product was
purified from 3% agarose gels, digested with Eco RI and Sma I, and ligated to
pBluescript vector. The identity of the sequence was confirmed by sequence
analysis. Cla I linearized plasmid was used as a template for cRNA synthesis
using commercial reagents from Promega (Madison, WI). The sizes of the
protected neurofibromin sequences were 301 and 255 nucleotides. Prior to
hybridizations, the amount and integrity of sample RNA were confirmed by
running equal 1 µg aliquots of each RNA specimen on a denaturing 2% agarose
gel and subsequently staining with ethidium bromide. The anti-sense probe
labeled radioactively with [α32P]-UTP was hybridized with sample RNA
(20 µg) in solution containing 80% formamide, 40 mM Pipes, 400 mM NaCl,
and 1 mM ethylenediaminetetraacetic acid disodium salt-2-hydrate at 52°C
overnight. The hybridization products were digested in a solution containing
RNase A (12 µg per ml) and RNase T1 (30 U per ml), 300 mM sodium
acetate, and 5 mM ethylenediaminetetraacetic acid disodium salt-2-hydrate for
1 h at 37°C to degrade unhybridized single-stranded RNA. The reactions were
terminated by adding 50 µg of proteinase K and 3.5 µl of 20% SDS into the
reaction mixture and by incubating at 37°C for 15 min. The samples were
subsequently purified by phenol-chloroform extraction and precipitated. The
neurofibromin sequence-specific mRNA-cRNA hybrids were electrophoresed
on denaturing gels (4.5% polyacrylamide/8 M urea) and exposed to X-ray films
(X-Omat). The integrity of the radiolabeled single-stranded cRNA probe was
verified in the same gels. In order to verify the efficiency of RNase treatment,
cRNA probe was added to reaction solution containing yeast RNA, not
expected to result in double-stranded RNA hybrids, but to result in a complete
degradation of the probe by RNase.
Reverse transcriptase polymerase chain reaction (RT-PCR) RNA were
isolated from fibroblasts that were grown in medium containing the highest
concentrations of PDGF (30 ng per ml) or TGF-β1 (5 ng per ml). Total RNA
(5 µg per reaction) was transcribed into single-stranded DNA in a 20 µl
reaction volume containing 9.5 U avian myeloblastosis virus reverse transcriptase
(Promega), avian myeloblastosis virus reverse transcriptase buffer (50 mM Tris-
HCl, pH 8.3, 50 mM KCl, 10 mM MgCl2, 10 mM dithiothreitol, 0.5 mM
spermidine), 0.5 mM of each of the four deoxynucleotides, 60 pmol of random
primer, and 20 U of rRNasin (Promega). The reaction was allowed to proceed
at 37°C for 60 min. For PCR, 1 µl of the RT reaction product was used as a
template in a 10 µl reaction containing 15 pmol of neurofibromin specific
primers NF1G.C and NF1G.D (Nishi et al, 1991) (see below) and/or 0.2 pmol
of β-actin specific primers 54 and 55 (Nudel et al, 1983) (see below), 0.2 mM
each of the deoxynucleotides, and 1 U of Dynazyme (Thermos brockianus, strain
F500, Finnzymes, Espoo, Finland). The reaction buffer contained 10 mM
Tris-HCl, pH 8.8, 50 mM KCl, 1.5 mM MgCl2, and 0.1% Triton-X-100.
Amplification was performed by incubating the mixture for 30 cycles of
denaturation (60 s at 94°C), annealing (60 s at 63°C), and extension (60 s at
72°C). In some reactions, neurofibromin and β-actin specific primer pairs were
used in the same reactions in order to achieve simultaneous amplification of
neurofibromin and β-actin sequences used as a reference template. In the
negative control samples, the template was omitted and PCR was performed
under the same conditions as other samples. The PCR products were analyzed
electrophoretically on 4% agarose gels (3% Nusieve GTG agarose, FMC,
Rockland, ME; and 1% type VII, Low Gelling agarose, Sigma) and stained
with ethidium bromide. The following oligonucleotides were used as primers
for the PCR reactions:
NF1G.C, 59 CAGAATTCCCCCCTCAACTTCGAAGT 39;
NF1G.D, 59 TGCGTGCTGCATCAAAGTTGCTTTTCAC 39;
54, 59 GCCGCCCTAGGATCCAGGGTGTGATGGTGGGTAT 39;
55, 59 GATGCCACAGAATTCCATACCCAGGAAGGAAGGC 39.
Antibodies Affinity-purified rabbit polyclonal antibody NF1GRP (D) raised
against synthetic peptide corresponding to amino acids 2798–2818 of the
predicted NF1 gene product was used for immunolabeling (cat # sc-67, Santa
Cruz Biotechnology, Santa Cruz, CA) (Gutmann et al, 1991).
Avidin-biotin immunolabeling The avidin-biotin immunolabeling was
carried out using a Vectastain ABC Kit (Vector Laboratories, Burlingame, CA).
Formalin fixed and paraffin-embedded specimens were cut to 5 µm sections
and deparaffinized with xylene. Sections were rehydrated in a decreasing series
of ethanol and incubated with 0.4% pepsin (Sigma) in 0.01 M HCl for 45 min
at 37°C to increase the immunoreactivity of the samples. Endogenous peroxidase
was blocked with 0.3% H2O2 in methanol for 30 min. Non-specific binding
was blocked using normal goat serum, diluted 1:100 in 0.05 M Tris buffered
saline (TBS, pH 7.5) for 2 h. The sections were incubated with primary
antibody NF1GRP (D) diluted 1:200 in TBS with 1% bovine serum albumin
at 4°C overnight, and washed in TBS at room temperature for 3 3 10 min.
The samples were subsequently incubated with nonimmune goat serum with
the same dilution as above for 20 min, and exposed to biotinylated anti-rabbit
IgG secondary antibody (1:220 in TBS with 1% bovine serum albumin) for
30 min, and to the avidin-peroxidase complex for 30 min. The sections were
incubated with the substrate 0.05% 3,3’-diaminobenzidine tetrahydrochloride
in TBS with 0.07% imidazole (E. Merck AG, Darmstadt, Germany) and 0.01%
H2O2 for 5 min. Finally, the samples were counterstained with hematoxylin,
dehydrated, and mounted. Control immunoreactions included the following:
(i) primary antibody was replaced with 1% bovine serum albumin (BSA)-TBS;
(ii) primary antibody was replaced with preimmune rabbit sera diluted 1:50–
400 in 1% BSA-TBS; (iii) primary antibody was preabsorbed with 10 3 M
excess of synthetic peptide used for immunization. In all controls, a faint
uniform background reaction was observed.
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Figure 1. Neurofibromin immunolabel-
ing is increased in healing skin wounds.
A post-operative skin sample containing an
area of a 16 d-old incision wound from a
35 y-old male was subjected to avidin-biotin
immunolabeling for neurofibromin [antibody
NF1GRP (D)] followed by hematoxylin
counterstain (see Materials and Methods).
Perilesional, apparently healthy skin (a, c)
harbors fibroblasts that display only a weak
immunosignal for neurofibromin. In (b), →
indicate the location of the primary wound
containing numerous dermal fibroblasts with
a readily detectable immunoreaction for
neurofibromin. (c, d) A higher magnification
of upper dermis from the same areas as in (a)
and (b). Scale bars, (a, b) 150 µm; (c, d) 20 µm.
Digital image analysis ABC-immunolabeled microscopic samples were
digitized using a Nikon Optiphot-2 microscope and digital image analyzer
using MCID/M2 (Version 5.0 Rev. 1.5) software (St. Catharine, Canada). To
demonstrate the changes in cytoplasmic neurofibromin immunoreactivity in
dermal fibroblasts, the intensities of the immunosignals were viewed using 256
levels of gray (8-bit mode) and changed into pseudocolor scale using MCID/
M2 look up table (LUT). Dark blue was selected to represent the background
intensity of immunoreaction, whereas light blue and green represent slightly
increased or markedly increased expression, respectively. Nuclei of the fibroblasts
and the epidermis were labeled with grey color.
Indirect immunofluorescence labeling Frozen sections, 5–7 µm thick, of
human scar and normal fetal and adult skin were cut on silanated glass slides.
Sections were fixed in 100% ethyl alcohol at –20°C for 15 min. To prevent
nonspecific binding, the samples were preincubated in phosphate-buffered saline
(PBS) supplemented with 1% BSA for 15 min. Antibody NF1GRP (D) was
diluted in 1% BSA-PBS, and incubated on the slides at 4°C for 20 h. Following
five 10 min washes in PBS, the slides were incubated with tetramethyl-
rhodamine isothiocyanate-conjugated anti-rabbit IgG (Dakopatts, Glostrup,
Denmark) at 20°C for 1 h and washed five times in PBS. The samples were
observed and photographed with a Leitz Aristoplan microscope equipped with
an epiilluminator, filters for tetramethyl-rhodamine isothiocyanate-fluorescence,
and camera attachment. Control immunoreactions included the following: (i)
primary antibody was replaced with 1% BSA-PBS; (ii) primary antibody was
replaced with preimmune rabbit sera diluted 1:50 in 1% BSA-PBS; or (iii)
primary antibody was preabsorbed with 10 3 M excess of synthetic peptide
that was originally used for immunization. In all controls, only a faint uniform
background fluorescence was observed.
RESULTS
Expression of neurofibromin is elevated in healing dermal
wounds Scars obtained 12 d to 23 mo after primary operation from
a total of 26 patients (aged 9–84 y) were analyzed for neurofibromin
using avidin-biotin immunolabeling. Control skin samples were
obtained from a total of 18 persons undergoing operations for cosmetic
reasons. The findings on control skin samples and apparently healthy
perilesional skin (Fig 1a, c) were in good agreement with previous
results (Hermonen et al, 1995; Peltonen et al, 1995), demonstrating
that the immunosignal for neurofibromin in dermal fibroblasts was
much less intense than in epidermal keratinocytes within each sample.
In contrast to findings on control skin and apparently healthy perilesional
skin, fibroblasts within scars of different ages displayed a readily
detectable immunosignal for neurofibromin (Figs 1b, d, 2a–c). The
intensity of neurofibromin immunoreactivity in scar fibroblasts did
not, however, necessarily correlate with the age of the scar, or the age
of the donor. Thus, it was not possible to conclusively determine a
certain time interval following primary wounding when the dermal
fibroblasts would be particularly active in neurofibromin expression,
because even the oldest scars contained localized areas harboring
fibroblasts intensely positive for neurofibromin. In summary, the results
demonstrated that increased immunoreaction for neurofibromin was
observed on the site of the original trauma in all scar samples analyzed,
and that the elevated dermal immunoreaction for neurofibromin in
healing tissue trauma may persist up to 23 mo, which was the age of
the oldest scar sample analyzed.
As the scar samples contained sharply localized areas of previously
lesional dermis surrounded by apparently intact tissue, isolation of RNA
for quantitative analyses representative of neurofibromin expression at
different stages of wound healing was not possible in the material that
was available to us.
Neurofibromin is expressed by keratinocytes and fibroblasts in
fetal skin Expression of neurofibromin at the protein level was
further studied in developing skin of 19 and 34 wk-old fetuses using
indirect immunofluorescence labeling. The results demonstrated that,
in contrast to normal adult skin, fetal dermis contained numerous
fibroblasts intensely positive for neurofibromin (Fig 3a). RNA samples
from fibroblasts cultured from the same tissue specimens were subjected
to northern transfer analysis with neurofibromin-specific cDNA probe.
The results demonstrated a 11–13 kb band representative of neurofib-
romin mRNA (Fig 3b). The hybridization signal was readily detectable
after a relatively short (4 d) exposure time that is in contrast to findings
on fibroblasts cultured from adult skin (see below).
Different PDGF isoforms exert selective effects on neurofibro-
min mRNA steady-state levels in fibroblasts cultured from
normal adult skin Fibroblasts cultured from normal human skin
were treated with 0.1, 1, 10, and 30 ng per ml of PDGF AA, AB, and
BB for 24 1 24 h. RNA was isolated from cell cultures and 7.5 µg of
total RNA was subjected to northern transfer analysis. The neurofib-
romin specific cDNA probe hybridized to 11–13 kb mRNA (Fig 4),
which is consistent with earlier studies reporting a large size for
neurofibromin mRNA (Wallace et al, 1990). Even though not often
discussed in the literature, northern transfer analyses of RNA isolated
from various tissues or cultured cells may display more than one large
band (e.g., Wrabetz et al, 1995) in addition to a 13 kb transcript
originally reported in Wallace et al (1990).
The hybridization signals for neurofibromin mRNA from cultured
adult fibroblasts became detectable after relatively long (2–4 wk)
exposure times, which is in contrast to findings on cultured fetal skin
fibroblasts (see above).
The results demonstrated that the treatment of cultured fibroblasts
with PDGF can upregulate the expression of neurofibromin by these
cells, and that the effects of different PDGF isoforms on neurofibromin
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Figure 2. Image analysis of healing wound reveals increased
neurofibromin immunosignal in resident fibroblasts. To enhance the
analysis of the intensities of neurofibromin immunosignal, the samples were
digitized using a Nikon Optiphot-2 microscope and a digital image analyzer.
The intensities of neurofibromin immunosignal were viewed using 256 levels
of gray, which were subsequently changed into pseudocolor scale using MCID/
M2 (version 5.0 Rev. 1.5) software (for details see Materials and Methods).
Green and light blue colors represent markedly increased or slightly increased
neurofibromin immunosignal, respectively. Dark blue was selected to represent
the background intensity of immunoreaction, whereas the nuclei of the
fibroblasts and the epidermis were labeled with grey color. Part (a) shows a
square area partially covering the same field as in Fig 1(b). The lower two
panels with a higher magnification show the cytoplasmic neurofibromin
immunoreactivity of the fibroblasts in the apparently normal skin (b) and in the
area of scar (c). Scale bars, (a) 250 µm; (b, c) 25 µm.
expression are selective. Specifically, PDGF AB isoform elevated
neurofibromin mRNA levels in a dose-dependent manner in repeated
experiments, whereas the maximal upregulatory effect on neurofibro-
min expression exerted by PDGF BB was reached with concentrations
as low as 1 ng per ml (Fig 4). Treatment of cultured fibroblasts with
PDGF AA, however, did not have any apparent effects on the
neurofibromin mRNA steady-state levels (not shown).
TGF-b1 upregulates neurofibromin mRNA levels in normal
skin fibroblasts in vitro To study the effects of TGF-β, fibroblast
cultures were treated with varying concentrations of TGF-β1 for
24 1 24 h, and harvested for RNA isolation. To enhance the detection
neurofibromin mRNA, total RNA (20 µg per sample) was subjected
to highly sensitive RNase protection assays with neurofibromin-specific
cRNA. The results indicated that TGF-β1 upregulated the expression
of neurofibromin RNA by cultured fibroblasts in a concentration-
dependent manner when used at concentrations of 0.5 and 5 ng
per ml (Fig 5).
Figure 3. Neurofibromin is expressed by keratinocytes and fibroblasts
in fetal skin. (a) Indirect immunofluorescence labeling of skin of a 19 wk-old
fetus with neurofibromin-specific antibody NF1GRP (D) (for details see
Materials and Methods). Note the positive immunoreaction in the epidermis and
in association with dermal fibroblasts. (b) Northern transfer analysis with 32P-
labeled neurofibromin sequence-specific cDNA of RNA isolated from fibroblasts
cultured from the same tissue specimen (10 µg per lane). A 4 d exposure results
in an intense hybridization signal as visualized by a 11–13 kb band representative
of neurofibromin mRNA. Scale bar, 20 µm.
Figure 4. Neurofibromin mRNA steady-state levels are differentially
upregulated by PDGF AB and BB in cultured normal human skin
fibroblasts. Fibroblast RNA was isolated from cultures treated with 0.1, 1, 10,
and 30 ng per ml of PDGF AB or BB for 48 h as described in Materials and
Methods. Total RNA (7.5 µg) was subjected to northern transfer analysis and
hybridized with a neurofibromin sequence-specific cDNA probe. → indicate
11–13 kb neurofibromin mRNA bands; arrowhead indicates migration position
of the 28 S ribosomal subunit. The lower panel shows the 28 S ribosomal units
as visualized by ethidium bromide staining of the filter after transfer to verify
even loading and transfer efficiency of the RNA. The resulting X-ray film was
scanned to digital format and reproduced as described in Materials and Methods.
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Figure 5. TGF-b1 upregulates neurofibromin mRNA levels in normal
human skin fibroblasts in vitro as demonstrated by RNase protection
assay. Cell cultures were treated with 0.5 and 5 ng per ml of TGF-β1 for 48 h
as described in Materials and Methods. The neurofibromin sequence-specific
anti-sense RNA (cRNA) probe labeled radioactively with [α32P]-UTP was
hybridized with sample RNA (20 µg) and the hybridization products were
subsequently digested with RNase A and RNase T1. The cRNA–mRNA
hybrids were electrophoresed on denaturing gels (4.5% polyacrylamide/8 M
urea) and exposed to X-ray films. Lane a, molecular weight ladder containing
MspI-digested, radiolabeled fragments of pBR322; lane b, radiolabeled full-
length neurofibromin specific cRNA probe prior to hybridization; lane c, probe
hybridized with yeast RNA (negative control); lane d, analysis of RNA from
nontreated fibroblasts; lanes e and f, cells treated with 0.5 and 5 ng TGF-β1
per ml. The sizes of the protected neurofibomin sequences were 255 and 301
nucleotides (for details see Materials and Methods).
Figure 6. Exposure of normal dermal fibroblasts to PDGF or TGF-b1
does not result in an altered ratio of neurofibromin type I and II mRNA
as demonstrated by RT-PCR. Lane a, 310 bp band of molecular weight
marker (X174/HaeIII); lane b, fibroblasts cultured in the presence of PDGF BB
(30 ng per ml) for 48 h; lane c, fibroblasts cultured without PDGF BB; lane d,
fibroblasts cultured with TGF-β1 (5 ng per ml); lane e, fibroblasts cultured
without TGF-β1. The 366 bp band represents type II neurofibromin mRNA
and the 303 bp band type I, respectively.
Exposure of cultured normal dermal fibroblasts to PDGF or
TGF-b1 does not result in an altered ratio of neurofibromin
type I and II mRNA In order to estimate potential neurofibromin
mRNA splice variant-specific effects exerted by PDGF or TGF-β1,
fibroblasts were cultured with the highest concentrations of PDGF
(30 ng per ml) and TGF-β1 (5 ng per ml) used in experiments described
above. Total RNA was subsequently extracted and used for reverse
transcription followed by PCR. RT-PCR demonstrated the presence
of neurofibromin mRNA in cultured fibroblasts (Fig 6). Specifically,
the use of oligonucleotide primers designated GC and GD by Nishi
et al (1991) resulted in the amplification of characteristic 303 and
366 bp cDNA representative of type I and II neurofibromin mRNA
splice variants, respectively. In these experiments, different isoforms of
PDGF or TGF-β1 did not cause apparent differences in type I/type
II neurofibromin mRNA ratio.
DISCUSSION
The results of this study demonstrate that 12 d to 23 mo-old scars
contained fibroblasts that displayed an intense immunosignal for tumor
suppressor protein neurofibromin. This is in marked contrast to findings
on intact skin in this and previous studies (Hermonen et al, 1995;
Peltonen et al, 1995). Our results suggest that upregulation of tumor
suppressor protein neurofibromin in fibroblasts may play a role in
normal response to tissue injury. Interestingly, a study by Sosnowski
et al (1993) has linked expression of ras proto-oncogenes to proper
wound healing. Specifically, living bovine corneal endothelium cells
that were microinjected with ras dominant interfering mutant protein
and subsequently stimulated by mechanical wounding, displayed an
altered wounding response as estimated by diminished fos expression,
lack of cell migration, and a block in DNA synthesis. It is tempting
to speculate that an activation of two counteracting elements, ras and
neurofibromin, in response to wounding is analogous to other situations
with simultaneous activation of pathways with opposite effects, such
as blood clotting and fibrinolytic cascades. In the case of activation of
ras and neurofibromin following trauma, the role of ras would be in
the initiation phase of the response, and neurofibromin may act among
factors limiting excessive response. Thus, the elevated expression of
neurofibromin by wound fibroblasts may be a factor contributing to
the restoration of the architecture of the injured tissue. It has also
been suggested that neurofibromin expression is increased in human
fibroblasts of astrocytic tumors as a result of positive feedback regulation
by increased levels of activated ras (Gutmann et al, 1996).
The in vitro results of this study identified PDGF and TGF-β as
potential mediators of neurofibromin upregulation during tissue repair.
Interestingly, PDGF-induced DNA synthesis and proliferation has been
demonstrated to include the activation of ras as well (Satoh et al, 1993;
Bornfeldt et al, 1995), and TGF-β1 has been shown to activate ras and
increase p21-ras protein in different cell culture systems (Yan et al,
1994; Teruel et al, 1996).
In this study, different isoforms of PDGF had selective effects on
neurofibromin expression by cultured fibroblasts, PDGF BB resulting
in maximal upregulation of neurofibromin mRNA levels when used
at concentrations as low as 1.0 ng per ml. The differences were not
quite unexpected because, for example, the number of receptors
recognizing the PDGF BB isoform has been reported to be 10–20
times higher than the number of receptors binding the PDGF AA
isoform in human dermal fibroblasts (Hart et al, 1988; Seifert et al,
1989), which in part may explain the different responses of cultured
cells to treatment with PDGF isoforms.
Potential relevance of the results to manifestations in
neurofibromatosis Some clinical evidence presented before the
cloning of the NF1 gene has been suggested to support a hypothesis
that the appearance and growth of neurofibromas may be associated
with prior or ongoing mechanical trauma (Riccardi, 1981, 1990).
Furthermore, the pathogenesis of neurofibromatosis is not determined
exclusively by the genetic NF1 defect. These findings include, for
example, that monozygous twins do not present identical clinical
findings (Åkesson et al, 1983; Huson, 1994). As our results suggest that
neurofibromin expression can be elevated due to mechanical trauma,
the response to extrinsic factors in NF1 patients might cause a situation
where (i) too little fully functional neurofibromin is produced as only
one allele can be used for transcription of nonmutated tumor suppressor
protein, and/or (ii) elevated production of mutated neurofibromin
results in impaired growth behavior and differentiation of the resident
cells. Depending on the anatomical site and cell type involved, the
responses may vary. For instance, neurofibromin accounts for 15% of
total rasGTPase-activating protein activity in fibroblasts (Kobayashi
et al, 1993). On the other hand, peripheral nerves may be particularly
sensitive to develop alterations in neurofibromatosis because neuro-
fibromin has been shown to play a critical role in the downregulation
of ras proteins in Schwann cells (Basu et al, 1992; DeClue et al, 1992;
Kim et al, 1995; Vogel et al, 1995). These cells have also been shown
to express PDGF B chain mRNA (Hardy et al, 1992) and PDGF
protein (Eccleston et al, 1993), and to display a mitogenic response to
PDGF stimulation (Hardy et al, 1992).
In summary, the results of this study demonstrate a localized increase
in neurofibromin in response to external stimuli, and that PDGF and
TGF-β can upregulate the expression of neurofibromin in vitro. Thus,
any event causing release of, for example, PDGF in tissues particularly
sensitive to regulation exerted by neurofibromin, such as peripheral
nerves, may cause aberrant response and growth in neurofibromatosis.
The results also suggests that a ‘‘second hit’’ in a form of somatic
mutations in lesional neurofibromatosis cells may not be needed for
the development of manifestations typical for neurofibromatosis.
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